Featured Research

from universities, journals, and other organizations

EPO Prevents Chemotherapy Cardiotoxicity, Study Suggests

Date:
December 26, 2007
Source:
Society for Experimental Biology and Medicine
Summary:
The use of several chemotherapeutic agents in oncology is limited by their cardiac toxicity. Recent experimental studies suggest that recombinant human erythropoietin (rhEPO) can be considered as a protective agent against cardiac ischemic injury. Here we show that pretreatment by rhEPO protects myocardium against cardiotoxicity induced by acute doxorubicin or trastuzumab exposure, using the isolated rat heart model. Further clinical investigations are now needed to explore the potential benefit of rhEPO in oncology.

Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. Although rare, cardiotoxicity is a serious complication of cancer treatment. Indeed, the use of chemotherapeutic agents such as anthracycline or trastuzumab in oncology is limited by their cardiac toxicity. Therefore, it is of interest to identify new protective agents preventing these adverse effects.

Related Articles


"The increasing use of doxorubicin and trastuzumab in adjuvant breast cancer therapy and the growing population of long-term pediatric cancer survivors mean that, more than ever, cardiotoxicity will continue to remain an important issue for oncology. Cardiomyopathy induced by chronic chemotherapy may result, at least in part, from acute cardiotoxic effects accompanying each drug exposure." said Professor Mireille Mousseau, head of the Department of Oncology.

The research team, led by Christophe Ribuot, a professor of pharmacology, explored the beneficial cardioprotective effect afforded by recombinant human erythropoietin (rhEPO) against various stresses, through experimental and clinical investigations.

"We observed for the first time that only a unique rhEPO administration prevents cardiac damage induced by an acute doxorubicin or trastuzumab exposure, using the isolated rat heart model." said the article's first author Amandine Ramond. "RhEPO administration could, therefore, be used during chemotherapy administration to reduce acute cardiotoxic effects accompanying each drug exposure and, potentially, to prevent long-term development of cardiomyopathy. Further clinical investigations are now needed to explore the potential benefit of rhEPO in oncology."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "Amandine Ramond and her colleagues have provided an insightful study demonstrating that rhEPO can reduce the cardiotoxic effects of chemotherapeutic agents, doxorubicin and trastzumab, in a rat heart model. If rhEPO has similar effects on humans then this study will be of substantial benefit to cancer patients worldwide."

The research article describing this work entitled "Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts" will be featured in the January 2008 issue of Experimental Biology and Medicine.


Story Source:

The above story is based on materials provided by Society for Experimental Biology and Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society for Experimental Biology and Medicine. "EPO Prevents Chemotherapy Cardiotoxicity, Study Suggests." ScienceDaily. ScienceDaily, 26 December 2007. <www.sciencedaily.com/releases/2007/12/071220123841.htm>.
Society for Experimental Biology and Medicine. (2007, December 26). EPO Prevents Chemotherapy Cardiotoxicity, Study Suggests. ScienceDaily. Retrieved April 24, 2015 from www.sciencedaily.com/releases/2007/12/071220123841.htm
Society for Experimental Biology and Medicine. "EPO Prevents Chemotherapy Cardiotoxicity, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2007/12/071220123841.htm (accessed April 24, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, April 24, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

85 Killed in Niger by Meningitis Since Start of Year

85 Killed in Niger by Meningitis Since Start of Year

AFP (Apr. 24, 2015) A meningitis outbreak in Niger has killed 85 people since the start of the year prompting authorities to close schools in the capital Niamey until Monday. Video provided by AFP
Powered by NewsLook.com
Anti-Malaria Jab Hope

Anti-Malaria Jab Hope

Reuters - News Video Online (Apr. 24, 2015) The world&apos;s first anti-malaria vaccine could get the go-ahead for use in Africa from October if approved by international regulators. Paul Chapman reports. Video provided by Reuters
Powered by NewsLook.com
3D Food Printing: The Meal of the Future?

3D Food Printing: The Meal of the Future?

AP (Apr. 23, 2015) Developers of 3D food printing hope the culinary technology will revolutionize the way we cook and eat. (April 23) Video provided by AP
Powered by NewsLook.com
Your Genes Could Influence How Much Mosquitoes Love You

Your Genes Could Influence How Much Mosquitoes Love You

Newsy (Apr. 23, 2015) New research suggests genetics play a big part in how appetizing you smell to mosquitoes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins